ELSEVIER

Contents lists available at ScienceDirect

Biochemical Pharmacology

journal homepage: www.elsevier.com/locate/biochempharm



Molecular docking and pharmacogenomics of *Vinca* alkaloids and their monomeric precursors, vindoline and catharanthine

Serkan Sertel ^{a,e,g}, Yujie Fu ^{b,c}, Yuangang Zu ^{b,c}, Blanka Rebacz ^d, Badireenath Konkimalla ^e, Peter K. Plinkert ^a, Alwin Krämer ^d, Jürg Gertsch ^f, Thomas Efferth ^{e,g,*}

- ^a Department of Otorhinolaryngology, Head and Neck Surgery, University of Heidelberg, Heidelberg, Germany
- ^b Key Laboratory of Forest Plant Ecology, Ministry of Education, Northeast Forestry University, Harbin, China
- ^c Engineering Research Center of Forest Bio-Preparation, Ministry of Education, Northeast Forestry University, Harbin, China
- ^d Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center and Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
- ^e Pharmaceutical Biology (C015), German Cancer Research Center, Heidelberg, Germany
- ^f Institute of Biochemistry and Molecular Medicine, University of Bern, Bern, Switzerland
- ^g Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, University of Mainz, Mainz, Germany

ARTICLE INFO

Article history: Received 17 November 2010 Accepted 24 December 2010 Available online 8 January 2011

Keywords: Centrosomal clustering Molecular docking Multidrug resistance Pharmacogenomics Vinca alkaloids

ABSTRACT

Vinblastine and vincristine are dimeric indole alkaloids derived from Catharanthus roseus (formerly: Vinca rosea). Their monomeric precursor molecules are vindoline and catharanthine. While vinblastine and vincristine are well-known mitotic spindle poisons, not much is known about vindoline and catharanthine. Vindoline and catharanthine showed weak cytotoxicity, while vinblastine, vincristine, and the semisynthetic vindesine and vinorelbine revealed high cytotoxicity towards cancer cells. This may reflect a general biological principle of poisonous plants. Highly toxic compounds are not only active towards predators, but also towards plant tissues. Hence, plants need mechanisms to protect themselves from their own poisons. One evolutionary strategy to solve this problem is to generate less toxic precursors, which are dimerized to toxic end products when needed. As shown by in silico molecular docking and biochemical approaches, vinblastine, vincristine and vinorelbine bound with high affinity to α/β -tubulin and inhibited tubulin polymerization, whereas the effects of vindoline and catharanthine were weak. Similarly, vinblastine produced high fractions of mono- and multipolar mitotic spindles, while vindoline and catharanthine did only weakly affect bipolar mitotic spindle formation. Here, we show that vinblastine contributes to cell death by interference with spindle polarity. P-glycoprotein-overexpressing multidrugresistant CEM/VCR1000 cells were highly resistant towards vincristine and cross-resistant to vinblastine, vindesine, and vinorelbine, but not or only weakly cross-resistant to vindoline and catharanthine. In addition to tubulin as primary target, microarray-based mRNA signatures of responsiveness of these compounds have been identified by COMPARE and signaling pathway profiling.

Crown Copyright © 2011 Published by Elsevier Inc. All rights reserved.

1. Introduction

Plants produce secondary metabolites as defense weapons against microbial infections by viruses, bacteria, or protozoa and parasites such as insects or worms as well as against herbivores. Many plants are poisonous, while others can serve as medicinal plants with pharmacological activity. As shown in a previous survey conducted by the National Cancer Institute (NCI), USA,

Abbreviations: ABC transporter, ATP-binding cassette transporter; HNSCC, head and neck squamous cell carcinoma; IC₅₀, 50% inhibition concentration; RMSD, root mean square deviations; mRNA, messenger RNA; NCI, national cancer institute.

E-mail address: efferth@uni-mainz.de (T. Efferth).

more than two thirds of all anticancer drugs established in anticancer therapy are natural products, derivatives of natural products or mimic bioactive principles of natural products [1].

Among the clinically established natural products with anticancer activity are the *Vinca* alkaloids vinblastine and vincristine and more recently, the semi-synthetic derivatives vindesine and vinorelbine, which are highly useful drugs for the treatment of certain malignancies.

Vinca alkaloids arrest tumor cells during mitosis by binding to tubulin and depolymerization of microtubules [2]. This leads to cell cycle arrest in mitosis [3]. Besides interaction of Vinca alkaloids with tubulins, other mechanisms upstream (e.g. membrane-bound drug efflux transporters) and downstream (e.g. signal transduction pathways, programmed cell death) also account to the drugs' efficacy towards cancer cells.

^{*} Corresponding author at: Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, University of Mainz, Staudinger Weg 5, 55128 Mainz, Germany. Tel.: +49 6131 3925751; fax: +49 6131 3923752.

Vinblastine and vincristine are dimeric indole alkaloids derived from *Catharanthus roseus* (formerly: *Vinca rosea*). Their monomeric precursor molecules are vindoline and catharanthine. While there is clear evidence for the action of vinblastine and vinblastine as mitotic spindle poisons, not much is known about the monomers vindoline and catharanthine.

Both precursor molecules are less cytotoxic than their dimeric drugs, vinblastine and vincristine. The question arises, whether this reflects a biological principle of poisonous plants. Poisonous natural products such as vinblastine and vincristine are effective defence mechanisms against herbivores and other predators. However, these compounds may also reveal toxicity to the plants themselves. Hence, they may generate and store large amounts of less toxic precursor molecules for self-protection, whereas the final synthesis of highly toxic end products occurs only upon appropriate external stimulation.

In the present investigation, we hypothesized that different cytotoxicities of monomeric precursors and dimeric end products should affect binding to the primary target of Vinca alkaloids, the microtubules. In addition, dimeric second-generation drugs, the semisynthetic vindesine and vinorelbine have been included in the study. A comparative analysis of functional effects of the above mentioned compounds on microtubule formation (effect on α/β tubulin polymerisation) has been carried out in vitro. The relative binding affinities of vindoline and catharanthine were estimated from Dixon plots assuming that all compounds either directly or indirectly (allosteric modulation) interfere with the [3H]-vinblastine binding sites in α/β -tubulin. The experimental data have been compared to molecular modelling studies. The binding of Vinca alkaloids to tubulin may not only cause inhibition of microtubule elongation, but may also affect mitotic spindle formation. The formation of multipolar mitotic spindles by inhibition of centrosomal coalescence has been anticipated as novel treatment strategy [4,5]. Therefore, we have analyzed the capacity of Vinca alkaoids to induce multipolar mitotic spindles. Finally, we have analyzed the role of drug resistance mechanisms for monomeric and dimeric Vinca alkaloids. We first analyzed cross-resistance of vincristine-resistant CEM/VCR1000 leukemia cells towards vindoline and catharanthine in comparison to vinblastine, vindesine, and vinorelbine. Then, we have analyzed other determinants of responsiveness towards Vinca alkaloids in the cell line panel of the NCI by means of COMPARE-analyses of microarray-based transcriptome-wide mRNA expression.

2. Material and methods

2.1. Compounds

Vindoline and cantharanthine were isolated from *Cataranthus roseus* as described [6]. Vinblastine sulphate, vincristine sulphate, vindesine sulphate salt, and vinorelbine ditartrate salt vindesine were obtained from Sigma–Aldrich (Taufkirchen, Germany). Vindoline and catharanthine are precursor molecules in the biosynthesis route, while vinblastine and vincristine are end products (Fig. 1). The entire biosynthesis pathway has previously been elucidated [7]. Vindoline and catharanthine were isolated from *Cataranthus roseus* by two of the authors (YF and YZ). Vindesine and vinorelbine are semi-synthetic derivatives and were obtained from Sigma–Aldrich (Taufkirchen, Germany).

2.2. Cell lines

Human CCRF-CEM leukemia cells were maintained in RPMI medium (Gibco, Eggenstein, Germany) supplemented with 10% fetal calf serum in a humidified 7% CO₂ atmosphere at 37 °C. Cells were passaged twice weekly. All experiments were performed

with cells in the logarithmic growth phase. The multidrug resistance gene 1 (*ABCB1*, *MDR1*)-expressing CEM/VCR1000 subline was maintained in 1000 ng/mL vincristine. The establishment of the resistant subline has been described [8]. Sensitive and resistant cells were kindly provided by Dr. A. Sauerbrey (Dept. of Pediatrics, University of Jena, Jena, Germany).

The HNSCC cell line SCC114 (oral squamous cell carcinoma) cells were cultured in Dulbecco's modified Eagle's Medium (DMEM, Gibco, Invitrogen, Karlsruhe, Germany) supplemented with 10% FCS (Biochrom AG, Berlin, Germany). When indicated, vindoline, catharanthine, or vinblastine were added to the cell culture medium for 24 h. In all experiments, the final DMSO concentration was <1%.

The panel of 60 human tumor cell lines of the Developmental Therapeutics Program of the NCI consisted of leukemia, melanoma, non-small cell lung cancer, colon cancer, renal cancer, and ovarian cancer cells, cells of tumors of the central nervous system, prostate carcinoma, and breast cancer. Their origin and processing have been previously described [9].

2.3. Sulforhodamine B assay

The determination of drug sensitivity in the NCI cell lines by the sulforhodamine B assay has been reported [10]. The 50% inhibition concentration (IC_{50}) values for vinblastine, vincristine, catharanthine, and vindoline have been deposited in the database of the database of the Developmental Therapeutics Program of the NCI (http://www.dtp.nci.nih.gov).

2.4. Growth inhibition assay

The *in vitro* response to drugs was evaluated by means of a growth inhibition assay as described [10]. Aliquots of 5×10^4 cells/mL were seeded in 24-well plates and compounds were immediately added at different drug concentrations to allow calculation of 50% inhibition concentration (IC₅₀) values. Cells were counted seven days after drug treatment. The resulting growth data represent the net outcome of cell proliferation and cell death.

2.5. Preparation of pure α/β -tubulin (>95%)

Tubulin was isolated as pure α/β -tubulin from fresh pig brain according to a previously described method [11]. Fresh brains were obtained from the local slaughterhouse and processed immediately without prior cooling. In brief, 150–200 g cleaned pig brain was put into ice-cooled depolymerization buffer (50 mM MES, 1 mM CaCl₂, adjusted to pH 6.9 with KOH) and homogenized in a Polytron mixer. The homogenate was centrifuged in a Sorvall SLA-1500 rotor at 14,500 rpm for 60 min. The supernatant was transferred into an Erlenmeyer flask in high-molar PIPES-buffer (1 M PIPES, 10 mM MgCl₂, 20 mM EGTA adjusted to pH 6.9 with KOH) plus ATP (1.5 mM final concentration) and glycerol (98%) ad 300 mL. The resulting suspension was mixed and incubated at 37 °C for 1 h. Aliquots were transferred into ultracentrifuge tubes and centrifuged in a Beckman Ti50.2 rotor at 32,500 rpm $(96,000 \times g)$ for 75 min at 30 °C. The microtubule protein pellets were suspended in depolymerization buffer and put on ice prior to ultracentrifugation at 4 °C. The procedure was repeated for two polymerization cycles (total of three cycles) and the final α/β -tubulin pellets were suspended in ice-cold Brinkley Buffer (BRB80; 80 mM PIPES, 1 mM MgCl₂, 1 mM EGTA adjusted to pH 6.8 with KOH) prior to shockfreezing in liquid nitrogen and subsequent storage at -80 °C. Purity and concentration of α/β -tubulin were determined by SDS-PAGE gel electrophoresis and spectrophotometrically ($A = \varepsilon \cdot c \cdot d$ with a given extinction coefficient of 115,000 M⁻¹ cm⁻¹) at 280 nm. This procedure typically yielded 60–100 mg of α/β tubulin per 100 g of brain.

Fig. 1. Chemical structures of Vinca alkaloids.

2.6. Radioligand displacement α/β -tubulin

Tubulin in BRB80 buffer (0.5 mL, 5–10 μ M) was incubated with two different concentrations of [G-³H]-vinblastine (American Radiolabeled Chemicals, Inc.) (5 and 10 μ M) on ice for 30 min. Different concentrations of unlabeled vindoline, catharanthine, vincristine, vindesine, or vinorelbine were added and the mixture was incubated at 37 °C for 30 min. DMSO was used as vehicle control. Bound radioactivity was separated by gel filtration on a Sephadex G50 column on micro columns and measured in a scintillation counter.

2.7. Turbidimetry analysis of polymer formation

Freshly thawed α/β -tubulin was centrifuged at $5000 \times g$ for 5 min at 5 °C and then incubated with additional BRB80 buffer, drugs, DMSO vehicle, GTP/glutamate (25 mM/2.7 M) and/or MAPs, respectively, in a 96-well plate in either 50 or 100 μ L volumes. Experiments were either carried out in a 96-well quartz plate or in normal 96-well polystyrene plates (Falcon). The polymerization was monitored real-time at 340 nm in a temperature-controlled TECAN GeniosPro spectrophotometer. Depending on the specific experiment, the temperature was set either to RT (actual

measuring temperature was 24–27 °C) or 37 °C. The concentration of DMSO was found to be highly critical, because concentrations >2% DMSO induced considerable MT formation. UV absorption of compounds was subtracted from absorption curves. All experiments, along with both negative (untreated α/β -tubulin) and vehicle controls, were carried out in triplicate. Experiments were performed at least with two different α/β -tubulin batches.

2.8. Immunofluorescence

Cells grown on cover slips were fixed in $-20\,^{\circ}\text{C}$ methanol/acetone (1:1) for 7 min and then blocked in 10% goat serum/PBS. The primary mouse monoclonal antibody to Eg5 (Transduction Laboratories, Lexington, KY) was incubated for 1 h following 30 min incubation with a fluorochrome-conjugated secondary antibody anti-mouse Cy3 (Jackson ImmunoResearch Laboratories, West Grove, PN). Immunostained cells were examined using a Zeiss Axiovert 200 M fluorescence microscope (Göttingen, Germany) and images were processed with Photoshop software (Adobe, Munich, Germany).

Kinesin-related motor protein Eg5 is a highly conserved plusend directed motor protein that localizes to mitotic spindle microtubules and is required for establishing a bipolar spindle.

2.9. Molecular docking of Vinca alkaloids on tubulin

The X-ray structure of tubulin–colchicines–vinblastine: stahmnin-like domain complex (SLD) was used as docking template throughout the docking calculations. The coordinates of vinblastine were extracted from the PDB file, obtained from the Brookhaven Protein Data Bank (PDB 1Z2B) [12]. Docking calculations were performed using AutoDock program (AutoDock 4.2, The Scripps Research Institute, La Jolla, CA, USA) installed on a Linux PC under the SuSe operating system. AutoDock is an automated and robust docking algorithm based on the Lamarckian genetic algorithm (GA) with several success rates in the virtual screening of ligands.

The 2D structures of vincristine, vinblastine, vinorelbine, videsine, cantharanthine and vindoline were energy-minimised and converted to 3D structures compatible for docking operation using an open source program PRODRG [13].

Prior to start of the docking operation, essential hydrogens and Gasteiger chargers were added to the macromolecule. In order to sample the binding site, a grid of 60 Å \times 60 Å \times 60 Å with a spacing of 0.375 Å was first computed. In total, 100 cycles of flexible ligand docking were performed in the grid representation of the receptor binding site, followed by scoring the ligand-receptor interaction. AutoDock clustering was performed based on similarities in binding modes and affinities in these cycles. The optimized orientations represent possible binding modes of the ligand within the site. The AutoDock docking output contains solutions ranked according to the scoring functions with information about the frequency of occurrence, mean energies, inhibition constant and low root mean square deviations (RMSD) within the cluster each defined by the 3D coordinates. PyMOL (Schrödinger, Portland, OR, USA) was used as visualization tool to further get a deeper insight on the binding modes obtained from docking [14].

2.10. Statistical analyses

The mRNA expression values of 60 cell lines of the genes of interest were selected from the NCI database (http://www.dtp.nci.nih.gov). The mRNA expression has been determined by microarray analyses [15,16]. COMPARE analyses were performed to produce rank-ordered lists of genes expressed in the NCI cell line panel. The methodology has been described previously in

detail [17]. Briefly, every gene of the NCI microarray database is ranked for similarity of its mRNA expression to the IC₅₀ values for *Vinca* alkaloids. To derive COMPARE rankings, a scale index of correlations coefficients (*R*-values) is created. In the standard COMPARE approach, greater mRNA expression in cell lines correlates with enhanced drug resistance, whereas in reverse COMPARE analyses, greater mRNA expression in cell lines indicates drug sensitivity.

The Ingenuity Pathway Analysis software (IPA) (Ingenuity Systems, Mountain View, CA, USA; http://www.ingenuity.com) was utilized to identify networks and pathways of interacting genes and other functional groups in genomic data. Using the IPA Functional Analysis tool, we were able to associate biological functions and diseases to the experimental results. Moreover, we used a biomarker filter tool and the Network Explorer for visualizing molecular relationships.

For hierarchical cluster analysis, objects were classified by calculation of distances according to the closeness of betweenindividual distances. All objects were assembled into a cluster tree (dendrogram). The merging of objects with similar features leads to the formation of a cluster, where the length of the branch indicates the degree of relation. The distance of a subordinate cluster to a superior cluster represents a criterion for the closeness of clusters as well as for the affiliation of single objects to clusters. Thus, objects with tightly related features appear together, while separation in the cluster tree increases with progressive dissimilarity. Recently, cluster models have been validated for gene expression profiling and for approaching molecular pharmacology of cancer [15,18]. Cluster analyses applying the WARD method were done with the WinSTAT program (Kalmia, Cambridge, MA, USA). Missing values were automatically omitted by the program, and the closeness of two joined objects was calculated by the number of data points they contained. In order to calculate distances between all variables included in the analysis, the program automatically standardizes the variables by transforming the data with a mean = 0 and a variance = 1.

Pearson's correlation test was used to calculate significance values and rank correlation coefficients as a relative measure for the linear dependency of two variables. This test was implemented into the WinSTAT Program. Pearson's correlation test determines the correlation of rank position of values. Ordinal or metric scaling of data is suited for the test and data are transformed into rank positions. There is no condition regarding normal distribution of the data set for the performance of Pearson's correlation test.

3. Results

3.1. Cytotoxicity

The NCI cell line panel has been tested for sensitivity towards vinblastine, vincristine, catharanthine, or vindoline. The mean $\log_{10} IC_{50}$ values of eight different tumor types for these compounds are shown in Fig. 2. Cell lines of all tumor types revealed high cytotoxicity with mean $\log_{10} IC_{50}$ values for vinblastine in a range of $-9.26 \pm 0.04 \, \text{M}$ (leukemia) to $-8.15 \pm 0.41 \, \text{M}$ (ovarian carcinoma) and for vincristine in a range of $-6.95 \pm 0.01 \, \text{M}$ (leukemia) to $-6.14 \pm 0.49 \, \text{M}$ (breast cancer). Catharanthine and vindoline displayed only weak activity.

3.2. Inhibition of tubulin polymerization by Vinca alkaloids

Vincristine potently inhibited microtubule assembly and catharanthine showed a less potent effect on α/β -tubulin polymerization (Fig. 3). Vindoline was not able to reach considerable inhibition of microtubule assembly, suggesting that this compound does not or only very weakly interact with α/β -tubulin.




Fig. 2. Log₁₀ IC₅₀ values for Vinca alkaloids. Mean values ± SEM of 60 cell lines were grouped according to their tumor origin.

In addition, we analyzed the semi-synthetic derivatives, vindesine and vinorelbine. Both drugs inhibited microtubule assembly in a comparable manner as vincristine (Fig. 3).

3.3. Uncompetitive inhibition of the binding [³H]vinblastine to tubulin by catharanthine

In competition experiments, catharanthine clearly interfered with [3 H]-vinblastine for α/β -tubulin binding in an apparently uncompetitive manner (Fig. 4). Uncompetitive inhibition takes place, when a tubulin ligand (here catharanthine) binds only to the complex formed between tubulin and vinblastine (the T–V complex).

3.4. Molecular docking

The X-ray structure of vinblastine bound to tubulin in a complex with the RB3 protein stathmin-like domain was selected as a docking template (PDB 1Z2B) [19]. The template and the




Fig. 3. Inhibition of tubulin polymerization by *Vinca* alkaloids. Purified α/β -tubulin (25 μM) was polymerized at 37 °C in BRB80 assembly buffer with GTP/glutamate (25 mM/2.7 M) and with increasing concentrations of test compounds (μM). Turbidity was measured at 340 nm after 45 min. Endpoints (Δ_{340}) mean values are plotted as a non-linear function of drug concentration \pm SEM (N = 3).

docking parameters, using AutoDock, were validated by docking the crystallographic structure of vinblastine into the binding site of the protein template. Docking results showed low RMSD values between the experimental and the calculated docked structure and set a good platform to reliably dock other structurally similar chemical molecules. *Vinca* alkaloids were individually docked into the validated grid defined in the crystal structure of α/β -tubulin for appropriate conformational search. Next, 100 cycles of docking with approximately 250,000 energy evaluations in each cycle were carried out without any flexibility constraints on the ligand. The results were finally analyzed upon setting identical conditions for docking the tubulin structure template with vincristine, vinblastine, vinorelbine, vindesine, catharanthine and vindoline chemical molecules throughout the operation (Fig. 5).

The final docking results show that vindesine, vincristine, vinorelbine and vinblastine posses a high-order in the frequency of occurrence in a cluster and closeness in parameters in terms of mean docking energy (-8.52, -8.50, -8.47 and -8.37 kcal/mol, respectively) and predicted inhibition constant (1.49, 2.05, 1.54, 1.67 μ M) as shown in Table 1. In contrast, vindoline and




Fig. 4. Dixon plot, uncompetitive inhibition of the binding [3 H]vinblastine to tubulin by catharanthine. [3 H]vinblastine at 5 μM (black circles) and 10 μM (white circles) was incubated with purified α/β -tubulin (10 μM) and catharanthine (0.5–5 μM). After centrifugal gel filtration on a Sephadex G50 column the bound [3 H]-vinblastine was measured by scintillation counting. Data points are mean values of three experiments. Dotted line shows putative K_i value.




Fig. 5. Molecular docking studies of *Vinca* alkaloids. Docking of (A) six *Vinca* alkaloids into a specific common α/β pharmacophore, (B) catharanthine, (C) vindoline, (D) vinblastine, (E) vincristine, (F) vindesine, and (G) vinorelbine.

catharanthine showed relatively low mean docking energies (-7.28 and -7.0 kcal/mol, respectively) and inhibition constants (4.72 and 7.34 μ M, respectively) (Table 1), which implies a low affinity to tubulin binding.

Table 1 Molecular docking of *Vinca* alkaloids to α/β -tubulin dimer.

Compound	Mean docking energy (kcal/mol)	Mean pK _i ^a value (μM)		
Vindesine	-8.52	1.49		
Vincristine	-8.50	2.05		
Vinorelbine	-8.47	1.54		
Vinblastine	-8.37	1.67		
Vindoline	-7.28	4.72		
Catharanthine	-7.00	7.34		

^a pK_i : predicted inhibitory constant.

The ligand–protein interaction was analyzed using the LPC tool [20]. Binding site analysis showed that interaction of *Vinca* alkaloids (except of catharanthine) with Asn249C was a conserved feature (Table 2). Interaction of Val177B was observed for four of the six *Vinca* alkaloids analyzed and interaction of Pro175B with three compounds (Table 2). No H-bond interaction of catharanthine to any amino acid in the pharmacophore was found. The four clinically established *Vinca* alkaloids revealed 12–15 residues involved in hydrophobic interaction with the ligand, whereas vindoline and catharanthine exerted hydrophobic interaction with only 9 residues each.

3.5. Induction of mono- and multipolar mitoses

To analyze whether vinblastine and its precursors, vindoline and catharanthine induce spindle multipolarity, SCC114 cells were

Table 2 Interaction of *Vinca* alkaloids at the *Vinca* pharmacophore of the α/β -tubulin dimer.

	Residues involved in H-Bond interaction with ligand	No of residues involved in hydrophobic interactions with the ligand	
Vinblastine	ASN249C; LYS176B; PRO175B; SER178B; TYR210B; VAL177B; VAL353C	13	
Vincristine	ASN249C; ASN329C; LYS336C; PRO222B; TYR210B; VAL177B	15	
Vindesine	ASN249C; ASN329C; PRO175B; VAL177B; VAL353C	12	
Vinorelbine	ASN329C; PRO175B; PRO222B; VAL353C	13	
Vindoline	ASN249C; ASN329C; PRO222B; VAL177B	9	
Catharanthine	None	9	

treated for 24 h with each of the three compounds and immunostained with an anti-Eg5 monoclonal antibody to visualize mitotic figures. Counterstaining of DNA was done using DAPI. As shown in Fig. 6, untreated SCC114 cells contained 6.6% monopolar, 85% bipolar, and 8.3% multipolar mitoses. Treatment with 100–300 nM vindoline led to a dose-dependent increase of monopolar mitoses up to 23.5%. At higher concentrations, the fraction of monopolar mitoses decreased. At doses of 250–500 nM vindoline, a weak increase of multipolar mitoses was recorded (12–15%). Above 500 nM vindoline, general cytotoxicity precluded further analysis of mitotic spindles in SCC114 cells. According to the increase of mono- or multipolar mitoses, the fraction of bipolar mitoses dose-dependently decreased in a range between 100 and 500 nM.

Catharanthine showed a different effect on spindle polarity than vindoline. As shown in Fig. 6, there was a strong increase of monopolar mitoses up to 37.5% and no increase of multipolar mitoses upon treatment with 150–210 nM catharanthine. Accordingly, the percentages of bipolar mitoses dose-dependently decreased from 84% (control) to 50% (210 nM). At higher concentrations, catharanthine was cytotoxic. Vinblastine induced a considerable percentage particularly of multipolar mitoses (Fig. 6). Representative examples of multipolar mitoses in SCC114 cells treated with vindoline, catharanthine, or vinblastine and bipolar mitoses in untreated control cells are depicted in Fig. 7.

3.6. Multidrug resistance

Since the activity of *Vinca* alkaloids may not only be determined by binding to tubulin as primary target, but also by mechanisms upstream of this target, we investigated the role of the multidrug resistance-conferring drug transporter, P-glycoprotein. We treated drug-sensitive, parental CCRF-CEM leukemia cells and vincristine-resistant CEM/VCR1000 cells with catharanthine, vindoline, and

four clinically established *Vinca* alkaloids. Calculation of the degrees of resistance from the IC $_{50}$ values revealed that vincristine was one order and vinblastine two orders of magnitude more cytotoxic towards CCRF-CEM cells than catharanthine or vindoline (Table 3), while vindesine was about two-fold less active than vincristine, vinorelbine was two orders of magnitude more active than vincristine. CEM/VCR1000 cells were 41.8-fold resistant towards vincristine as compared to the parental CCRF-CEM cell line. Interestingly, CEM/VCR1000 cells showed higher degrees of resistance (56.2- to 341.9-fold, respectively) towards vinblastine, vindesine, or vinorelbine than the resistance-selecting agent, vincristine itself. Degrees of resistance towards catharanthine or vindoline were only low (\sim 2-fold) (Table 3).

3.7. Cross-resistance

To further analyze determinants of resistance and sensitivity towards *Vinca* alkaloids, we took advantage of the database of the Developmental Therapeutics Program of NCI, USA. We first analyzed the cross-resistance profile of the NCI tumor cell panel to *Vinca* alkaloids. There was a highly significant correlation between the $\log_{10} IC_{50}$ values for vinblastine and vincristine (R = 0.789; $P = 6.5 \times 10^{-16}$), whereas vincristine cytotoxicity did not correlate with catharanthine or vindoline activity (Table 4). The $\log_{10} IC_{50}$ values for catharanthine were significantly associated with those for vindoline (P = 0.01), but at a low R-value (0.310). Other relationships were not found.

3.8. COMPARE analyses of microarray data

Next, we performed COMPARE analyses of the IC₅₀ values for vinblastine, vincristine, vindoline, and catharanthine and the transcriptome-wide mRNA expression of the NCI cell lines to produce scale indices of correlation coefficients. We first




Fig. 6. Induction of mono- and multipolar mitoses and decrease of bipolar mitoses after treatment of SCC114 cells for 24 h with vindoline, catharanthine, or vinblastine as determined by immunofluorescence.




Fig. 7. Representative immunofluorescence images of a bipolar mitosis of untreated SCC114 cells (upper panel) and of multipolar mitoses in SCC114 cells treated with vinblastine (second panel), catharanthine (third panel), or vindoline (lower panel) for 24 h.

performed a standard COMPARE analysis in which cell lines that were most inhibited by Vinca alkaloids (lowest IC₅₀ values) were correlated with the highest mRNA expression levels of genes. Genes with correlation coefficients of R > 0.5 are shown in Table 5. If more than 10 genes met this criterion, only the top 10 genes for each compound are listed. If more than one clone of the same gene appeared in the COMPARE ranking lists, only the clone with the best R-value was displayed. These genes may be considered as

Table 3Resistance profile of multidrug-resistant human CEM/VCR1000 leukemia cells to *Vinca* alkaloids.

	CCRF-CEM (mean $IC_{50} \pm SD$, μ M)	CEM/VCR1000 (mean IC ₅₀ ±SD, μM)	Degree of resistance
Catharanthine	13.7 ± 4.5	29.8 ± 1.22	2.2
Vindoline	14.0 ± 6.28	24.1 ± 3.67	1.7
Vincristine	$\boldsymbol{1.92 \pm 0.14}$	$\textbf{80.2} \pm \textbf{10.2}$	41.8
Vinblastine	$\boldsymbol{0.468 \pm 0.06}$	26.3 ± 1.6	56.2
Vindesine	$\boldsymbol{2.93 \pm 0.02}$	229 ± 24.4	78.2
Vinorelbine	$\textbf{0.031} \pm \textbf{0.006}$	10.6 ± 0.89	341.9

possible candidate genes, which determine cellular resistance to *Vinca* alkaloids. Afterwards, reverse COMPARE analyses were done (R < -0.5), which correlated the most inhibited cell lines with the lowest gene expression levels (Table 5). This approach provided genes that are associated with cellular sensitivity to *Vinca*

Table 4Correlation of $\log_{10} IC_{50}$ values for *Vinca* alkaloids of the NCI cell line panel.

	Vindoline	Vinblastine	Vincristine
Catharanthine			
R-Value	0.311	0.015	-0.015
P-Value	0.010	0.455	0.455
Vindoline			
R-Value		-0.088	0.078
P-Value		0.261	0.283
Vinblastine			
R-Value			0.789
P-Value			6.518×10^{-16}

^{*}P-Values, Pearson correlation test (implementation of WinSTAT program, Kalmia, Cambridge, MA, USA).

Table 5
Genes identified by standard or reverse COMPARE analyses whose mRNA expression in the NCI cell line panel correlated with IC50 values for Vinca alkaloids.

Catharanthine: Standard 0.591 0.591 0.554 0.55 0.548 0.546 0.545 0.543 Catharanthine: Reverse 0 -0.625	FLNB NFE2L3 Null Null	AF042166 NM_004289	GC55768 GC183078	Filamin B, beta (actin binding protein 278)	Filamin family member; links transmembrane proteins with actin cytoskeleton; repair
0.554 0.55 0.548 0.546 0.545 0.543 Catharanthine: Reverse 0 -0.625	NFE2L3 Null Null				transmembrane proteins
0.55 0.548 0.546 0.545 0.543 Catharanthine: Reverse (-0.625	Null Null	NM_004289	GC183078	binding protein 278)	
0.55 0.548 0.546 0.545 0.543 Catharanthine: Reverse 0 -0.625	Null Null	NM_004289	GC183078		with actin cytoskeleton; repair
0.55 0.548 0.546 0.545 0.543 Catharanthine: Reverse (-0.625	Null Null	NM_004289	GC183078		
0.55 0.548 0.546 0.545 0.543 Catharanthine: Reverse (-0.625	Null Null	NM_004289	GC183078		of vascular injuries
0.548 0.546 0.545 0.543 Catharanthine: Reverse 0 -0.625	Null			Rho-guanine nucleotide	Leucine zipper transcription factor
0.548 0.546 0.545 0.543 Catharanthine: Reverse (-0.625	Null			exchange factor	family member; involved in
0.548 0.546 0.545 0.543 Catharanthine: Reverse 0 -0.625	Null			-	antioxidant response
0.548 0.546 0.545 0.543 Catharanthine: Reverse (-0.625	Null	AA455079	GC148639	Unknown	Unknown
0.546 0.545 0.543 Catharanthine: Reverse 0 -0.625		AI940225	GC79478	Unknown	Unknown
0.545 0.543 Catharanthine: Reverse 0 -0.625	PODXL	U97519	GC30864	Podocalyxin-like	Anti-adhesin
0.543 Catharanthine: Reverse (-0.625 -0.589	Null	AA010617	GC39732	Unknown	Unknown
Catharanthine: Reverse (-0.625 -0.589	Null	NM_022448	GC189007	Unknown	Unknown
-0.625 -0.589		NW_022448	GC103007	Olikilowii	Olikilowii
-0.589		A1221 402	CCC1102	Diago James (Descarbile)	Mambana associated associate
	DLGAP2	AI221403	GC61102	Discs, large (Drosophila)	Membrane-associated guanylate
				homolog-associated	kinase; neuronal cell signaling
				protein 2	
	Null	R28285	GC93180	Unknown	Unknown
-0.575	Null	R07477	GC92891	Unknown	Unknown
-0.527	Null	AA747713	GC49278	Unknown	Unknown
-0.526	Null	AI972104	GC80541	Unknown	Unknown
-0.518	Null	AI382058	GC64460	Unknown	Unknown
-0.505	Null	T95652	GC95840	Unknown	Unknown
-0.504	TFIP11	AL080147	GC16441011	Tuftelin interacting protein	Spliceosome disassembly;
				81	pre-mRNA splicing
-0.503	IKZF4	AI261467	GC617224	IKAROS family zinc finger	Ikaros transcription factor
0.505	III I	711207 107	GC017221	ne mos ranny zme miger	family member
-0.502	KCTD15	AA018217	GC39879	Potassium channel	Unknown
-0.302	KCIDIS	AA018217	GC35075		Olikilowii
				tetramerization domain	
v	4DADE			containing 15	
Vindoline: Standard CON		NN 046464	66406004		** 1
0.745	Null	NM_016164	GC186831		Unknown
0.718	Null	AI688023	GC70500		Unknown
0.715	ZNF414	AW291109	GC169427	Zinc finger protein 414	Transcriptional regulation
0.674	FBXO21	U79257	GC191569	F-box protein 21	Phosphorylation-dependent
					ubiquitination
0.657	RAB3B	M28214	GC32518	RAS family member 3B	Vesicular protein transport
				-	(by similarity)
0.652	HAS1	NM_001523	GC181059	Hyaluronan synthase 1	Constituent of the extracellular
				3	matrix; wound healing and tissue
					repair; tumor metastasis
0.651	KIAA1267	AL042870	GC82405	KIAA1267	Unknown
0.643	C19orf47	BE297801	GC172893	Chromosome 19 open	Unknown
0.045	C1301J47	BL237801	GC172033	•	Olikilowii
0.644	NL-11	MZZZEE	CC002.41	reading frame 47	Halmann
0.644	Null	M73255	GC90241	Unknown	Unknown
0.637	Null	M15205	GC32801	Unknown	Unknown
Vindoline: Reverse COM					
-0.651	Null	AA894854	GC51907	Unknown	Unknown
-0.636	ZCWPW2	AI677721	GC69927	Zinc finger, CW type	Zinc-binding protein
				with PWWP domain 2	
					Splicing factor compartment-
					associated serine kinase
-0.633	PSKH1	W25248	GC98337	Protein serine kinase H1	Intranuclear SR-protein traffic,
					pre-mRNA processing
-0.631	Null	AI677570	GC69940	Unknown	Unknown
-0.621	Null	AI668886	GC69495	Unknown	Unknown
-0.612	RHAG	AI052264	GC57850	Rh-associated glycoprotein	Transports ammonium and carbon
-0.012	MIAG	A1032204	GC37630	Kii-associated giycoproteiii	•
					dioxide across the blood cell
0.000	NT11	41022507	6676404	Halmanna.	membrane
-0.608	Null	AI823587	GC76424	Unknown	Unknown
-0.607	Null	AA805746	GC50354	Unknown	Unknown
-0.602	Null	R62547	GC93996	Unknown	Unknown
-0.598	Null	AA876132	GC51488	Unknown	Unknown
Vinblastine: Standard CO	OMPARE				
0.531	N21238	GC90658	Null	Unknown	Unknown
					Microtubule-associated protein;
					calmodulin-regulated
	MAP6	AI885733	GC77780	Microtubule-associated protein 6	Protein involved in microtubule
0.514					stabilization
0.514		CC070C4	Null	Unknown	Unknown
0.514	H79317	GC8/9h4	INUD		
0.507	H79317 MPARE	GC87964	INUII		Chichowh
		GC87964 U66689	GC29666	ATP-binding cassette, sub-family C	ATP-binding cassette (ABC)

Table 5 (Continued)

COMPARE coefficient	Gene symbol	GeneBank Acc. No.	Pattern ID	Gene name	Gene function
					Glutathione conjugates as
					leukotriene-c4 (LTC4) and
					N-ethylmaleimide S-glutathione
					(NEM-GS)
-0.684	Null	AF338650	GC154580	Unknown	Unknown
-0.671	CLDN1	AI889132	GC77925	Claudin 1	Claudin family member; integral
					membrane protein and
					component of tight junctions
-0.668	KLF8	AI821447	GC160084	Kruppel-like factor 8	Sp/KLF transcription factor family
					member; regulation of epithelial to
					mesenchymal transition
-0.662	Null	AI884781	GC160541	Unknown	Unknown
-0.632	Null	R26843	GC93170	Unknown	Unknown
Vincristine: Standard Co					
0.557	ENTPD1	AA493246	GC45226	Ectonucleoside	Hydrolysis of ATP in the nervous
				triphosphate	system and prevention of
				diphosphohydrolase 1	platelet aggregation
0.52	Null	AA229646	GC42534	Unknown	Unknown
0.518	LOC648987	AI056871	GC57995	Hypothetical LOC648987	Unknown
Vincristine: Reverse CO		A E 4 0 4 4 2 2	66450544		B 1 .: 6 6 . 1 !:
-0.762	GNMT	AF101477	GC152741	Glycine N-methyltransferase	Regulation of of metabolism
0.676	DDI D	A F2 40020	CC1E4CEC	Due la ation de compton	of methionine
-0.676 -0.674	PRLR	AF349939	GC154656	Prolactin receptor Unknown	Prolactin receptor Unknown
-0.674	Null	AI820661	GC160054	CL2/adenovirus E1B	Unknown
-0.674	BNIPL	W69365	GC99195	19 kD interacting protein like	Involved in apontosis
-0.674 -0.673	Null	AW300488	GC99193 GC169739	Unknown	Involved in apoptosis Unknown
-0.673 -0.671	TGFB3	103241	GC178532	Transforming	Member of the TGF-beta family;
-0.071	IGIDS	J03241	GC176332	growth factor, ®3	involved in embryogenesis and
				growth factor, (B)3	cell differentiation
-0.65	Null	AC004142	GC38728	Unknown	Unknown
-0.663	CLDN1	NM 021101	GC38728 GC188640	Claudin 1	Claudin family member; integral
0.005	CLDIII	1111_021101	30100040	Ciadaii 1	membrane protein and component
					of tight junctions
-0.653	KIAA1161	AB032987	GC151276	KIAA1161	Putative glucosidase (by similarity)

Information on gene functions was taken from the OMIM database, NCI, USA (http://www.ncbi.nlm.nih.gov/Omim/) and from the GeneCard database of the Weizman Institute of Science, Rehovot, Israel (http://www.bioinfo.weizmann.ac.il/cards/index.html).

alkaloids. A comparison showed that no genes appeared in association with more than one of the compounds, indicating that different genes may determine cellular response to these compounds.

3.9. Hierarchical cluster analyses

The genes obtained by standard and reverse COMPARE analyses for vindoline, catharanthine, vinblastine and vincristine were




Fig. 8. Dendrograms of hierarchical cluster analysis obtained from mRNA expression of genes correlating with log₁₀ IC₅₀ values for (A) catharanthine, (B) vindoline, (C) vinblastine, and (D) vincristine. The dendrograms show the clustering of the NCI cell lines.

Table 6Separation of clusters of the NCI cell line panel obtained by hierarchical cluster analysis shown in Fig. 8 in comparison to *Vinca* alkaloids. The log₁₀ IC₅₀ median values (M) of each compound were used as cut-off values to define cell lines as being sensitive or resistant.

	Partition	Cluster 1	Cluster 2	Cluster 3	χ^2 test
Catharanthine $(n=48)$					
Sensitive	<-4.358	5	9	10	
Resistant	>-4.358	0	5	19	P = 0.01147
Vindoline $(n=48)$					
Sensitive	<-3.786	9	1	14	
Resistant	>-3.786	0	11	13	$P = 1.69 \times 10^{-4}$
Vinblastine $(n = 58)$					
Sensitive	<-9.130	3	9	6	
Resistant	>-9.130	10	13	17	N.S.
Vincristine $(n=58)$					
Sensitive	<-6.8955	10	7	12	
Resistant	>-6.8955	5	3	21	N.S.

N.S., not significant (P > 0.05).

subjected to hierarchical cluster analysis to obtain a dendrogram, where the cell lines are arranged according to their expression profile of these genes. The dendrogram for each of the *Vinca* alkaloids investigated can be divided into three major cluster branches (Fig. 8). Then, the median $\log_{10} IC_{50}$ values for *Vinca*

alkaloids were used as cut-off threshold to define cell lines as being sensitive or resistant. As can be seen in Table 6, the distribution of sensitive or resistant cell lines was significantly different between the branches of the dendrograms for catharanthine or vindoline, indicating that cellular response to these two *Vinca* alkaloids was




Fig. 9. Assignment of biological functions of gene products associated with cellular response towards catharanthine and vindoline. Genes identified by COMPARE analyses (Table 5) were subjected to Ingenuity pathway analysis software. Top 10 biological functions of genes associated with response to (A) catharanthine and (B) vindoline.

predictable by these genes. Statistical significant results were not obtained for vinblastine or vincristine, indicating that the genes identified by microarray and COMPARE analyses did not predict cellular response to these two drugs.

3.10. Ingenuity pathway analyses

As a next step, we employed signaling route analyses. The genes identified by microarray and COMPARE analyses were subjected to Ingenuity Pathway Analysis software (version 6.5). Several groups of biological functions for genes were found to be significant in that they contained more of the identified genes than expected by chance. The genes determining sensitivity or resistance to catharanthine belonged to groups with the following biological functions: cell-to-cell signaling and interaction, developmental disorder, genetic disorder, and hematological system and development and function and other groups (Fig. 9A). The most important groups of genes determining cellular response to vindoline were drug metabolism, molecular transport, small molecule biochemistry and genetic disorder (Fig. 9B). Since the genes identified by COMPARE analyses did not significantly predict sensitivity and resistance to vinblastine or vincristine (Table 6), signaling pathway analyses were not applied for these two drugs.

4. Discussion

In the present investigation, we analyzed the cytotoxic potential of vindoline and catharanthine, two precursors of the mitotic spindle poisons, vinblastine and vinblastine. In addition to these natural products, the semi-synthetic derivatives, vindesine and vinorelbine of the second-generation have been investigated.

A striking feature was that the monomeric precursors, vindoline and catharanthine, were less cytotoxic towards cancer cells than the dimeric drugs, vinblastine and vincristine. This may reflect a general biological principle of poisonous plants. Highly toxic compounds are not only active towards predators, but also towards plant tissues. Hence, plants need mechanisms to protect themselves from their own poisons. One evolutionary strategy to solve this problem is to generate less toxic precursors, which are dimerized to toxic end products when needed. Storage of large amounts of the less toxic precursors, vindoline and catharanthine, is possible without harm for plants. Upon appropriate stimulation, high amounts of the toxic compounds vinblastine and vincristine can rapidly be synthesized by the plants. This hypothesis is supported by the fact that radical oxygen species foster the biosynthesis of vinblastine and vinblastine from its precursors, vindoline and catharanthine [7]. Exposure of periwinkle plants with H₂O₂ induced dimerization of the precursors to vinblastine [21]. Translating this experimental data to real life situations could mean that leaves attacked by plant-eating herbivores may be exposed to higher amounts of oxygen and radical oxygen species, which act as stimulus to defend the plant against the herbivore by vinblastine and vincristine production.

Microtubules are crucial for chromosomal segregation during mitosis. Clinically established *Vinca* alkaloids act as mitotic spindle poisons by inhibition of tubulin polymerization. Many cancer cells contain supernumerary centrosomes, which may contribute to aneuploidy induction *via* multipolar mitotic spindle formation. However, since spindle multipolarity is antagonistic to cell viability, tumor cells have developed centrosomal clustering mechanisms to prevent multipolar spindle formation by coalescence of multiple centrosomes into two functional spindle poles [5,22]. Inhibition of centrosome clustering represents a novel strategy for cancer drug development and leads to the formation of multipolar spindles with subsequent cell death induction. SCC114 is an oral squamous carcinoma cell line characteristic for the

phenotype of centrosomal clustering [4]. Even though the majority of the cell population harbours supernumerary centrosomes, only a few mitotic cells form multipolar spindles. The residual cell population coalesces their centrosomes into two spindle poles, thus, being able to divide in a bipolar manner. In the present investigation, treatment with vinblastine induced the formation of multipolar spindles in SCC114 cells in a considerable fraction of mitoses. In contrast, treatment with much higher concentrations of both, catharanthine or vindoline, only led to very few cells showing spindle multipolarity. This indicates vinblastine may in part trigger cell death, similar to other drugs that interfere with tubulin polymerization, by induction of spindle multipolarity [4]. Importantly, the capacity for multipolar spindle induction of the drugs analyzed clearly correlated with the cytotoxicity of the compounds, i.e. the highly cytotoxic vinblastine better induced multipolar spindle formation than the weakly cytotoxic vindoline or catharanthine. However, whether the induction of spindle multipolarity by vinblastine is indeed due to centrosomal declustering needs to be further examined.

It has previously been reported that the vindoline moiety is necessary for anchoring, while the catharanthine moiety confers cytotoxicity [23]. This view is conceivable with our molecular docking data showing that the weakly cytotoxic vindoline shares the residue Asn249C as binding partner for vinblastine, vincristine, vindesine, and vinorelbine, whereas the intermediate cytotoxic catharanthine did not bind to any amino acid at all. This may also contribute to differential effects on the formation of mono- and multipolar mitotic spindles.

Remarkably, the less cytotoxic precursors were also less cross-resistant in multidrug-resistant CEM/VCR1000 cells (2-fold *versus* 40-to 340-fold). Because they are less toxic, there is no need for cancer cells to extrude them out of the cell by P-glycoprotein. It is unknown why the resistance of the selecting agent, vinblastine in CEM/VCR1000 is less than the cross-resistance towards non-selecting *Vinca* alkaloids (vincristine, vindesine, vinorelbine). ATP-binding cassette (ABC) transporters are not only relevant for multidrug resistance of tumor cells, but are also widely distributed in microbiology as detoxification mechanisms for xenobiotics. From an evolutionary point of view, there is less need to extrude less toxic compounds out of cells than toxic ones. ABC transporters are part of the Phase I–III system of enzymes and transporters in mammals to cope with xenobiotic compounds taken up with nutrition.

Interestingly, a high degree of cross-resistance was observed between vinblastine and vincristine, but between the precursors, vindolidine and catharanthine, and vinblastine or vincristine. This may indicate similar modes of action of vinblastine and vincristine, but not of vindoline and catharanthine. This assumption drawn from correlation analyses was substantiated by measurement of microtubule formation. The weakly active vindoline did not inhibit tubulin polymerization and the moderately cytotoxic catharanthine inhibited tubulin polymerization only at higher concentrations as compared to the highly cytotoxic drugs vinblastine, vincristine, and vinorelbine. This result underlines the importance of tubulin as primary target of *Vinca* alkaloids in cancer therapy. Vinblastine, vincristine, vindesine and vinorelbine revealed a considerably higher binding affinity to the Vinca pharmacophore on tubulin as their precursors, vindoline or catharanthine. A closer inspection of amino acids in the binding region showed that all compounds except catharanthine attached to the residue Asn249C. In addition to Asn249C, each compound, except catharanthine showed H-bond interactions to variable other amino acids. Whereas vinblastine, vincristine, and vinblastine bound to 5-7 amino acids in our in silico docking approach, vindoline bound to only four residues and catharanthine did not show considerable interaction with amino acids in the pharmacophore. Similarly, the number of hydrophobic interactions of the clinically established *Vinca* alkaloids was higher than that of vindoline or catharanthine. This speaks for weaker interactions of vindoline and catharanthine with tubulin than of the other drugs, which nicely compares to the results on inhibition of tubulin polymerization in our biochemical assay.

In addition to binding to tubulin as primary target and Pglycoprotein as upstream mechanism of drug resistance, other molecular determinants for cellular response towards Vinca alkaloids may also be taken into account. Therefore, we performed COMPARE analyses of microarray-based transcriptome-wide mRNA expression profiling. It was of interest that the mRNA expression different genes (or still not assigned coding regions) correlated with sensitivity or resistance to catharanthine or vindoline, but not to vinblastine or vincristine. This may indicate that tubulin as common target may be of utmost importance for the highly cytotoxic vinblastine and vincristine. The weakly cytotoxic catharanthine and vindoline, which also only weakly bind to tubulin may have other determinants of response of tumor cells. Therefore, the hierarchical clustering were statistically significant for catharanthine or vindoline, but not for vinblastine or vincristine

The only gene which appeared in reverse COMPARE analyses of both vinblastine and vincristine was claudin 1 (*CLDN1*). Claudins are proteins constituting tight junctions at the blood brain barrier. It has been reported that components of tight junctions confer resistance to vinblastine [24]. Hence, the role of claudin 1 for cellular response towards *Vinca* alkaloids merits further investigation in the future.

In conclusion, we found that the monomers, vindoline and catharanthine, showed weak cytotoxicity, respectively, while dimeric vinblastine, vincristine, vindesine, and vinorelbine revealed high cytotoxicity towards cancer cells. As shown by in silico molecular docking approaches and biochemical experiments in vitro, vinblastine, vincristine and vinorelbine bound with high affinity to α/β -tubulin and inhibited tubulin polymerization, whereas the effects of vindoline and catharanthine were weak. Similarly, vinblastine produced high rates of multipolar mitotic spindles, while vindoline and catharanthine did only weakly affect bipolar mitotic spindle formation. P-glycoprotein-overexpressing multidrug-resistant CEM/VCR1000 cells were highly resistant towards vincristine and cross-resistant to vinblastine, vindesine, and vinorelbine, but not or only weakly cross-resistant to vindoline and catharanthine. In addition to tubulin as primary target, microarray-based mRNA signatures of responsiveness of these compounds have been identified by COMPARE and signaling pathway profiling.

Conflict of interest

There is no conflict of interest.

References

- [1] Cragg GM, Grothaus PG, Newman DJ. Impact of natural products on developing new anti-cancer agents. Chem Rev 2009;109:3012–43.
- [2] Okouneva T, Hill BT, Wilson L, Jordan MA. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Mol Cancer Ther 2003;2:427–36.
- [3] Gidding CE, Kellie SJ, Kamps WA, de Graaf SS. Vincristine revisited. Crit Rev Oncol Hematol 1999;29:267–87.
- [4] Rebacz B, Larsen TO, Clausen MH, Ronnest MH, Loffler H, Ho AD, et al. Identification of griseofulvin as an inhibitor of centrosomal clustering in a phenotype-based screen. Cancer Res 2007;67:6342–50.
- [5] Leber B, Maier B, Fuchs F, Chi J, Riffel P, Anderhub S, et al. Proteins required for centrosome clustering in cancer cells. Sci Transl Med 2010;2(33):ra38.
- [6] Zhang L, Yang L, Niu H, Zu Y. Separation of vindoline, catharanthine and vinblastine from catharanthus roseus (l.) g.Don with macroporous adsorption resin. J Chem Ind Eng (China) 2008;59:607–14.
- [7] El-Sayed M, Verpoorte R. Catharanthus terpenoid indole alkaloids: biosynthesis and regulation. Phytochem Rev 2007;6:277–305.
- [8] Kimmig A, Gekeler V, Neumann M, Frese G, Handgretinger R, Kardos G, et al. Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells. Cancer Res 1990;50:6793–9.
- [9] Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988;48:589–601.
- [10] Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, et al. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 1990;82:1113–8.
- [11] Castoldi M, Popova AV. Purification of brain tubulin through two cycles of polymerization-depolymerization in a high-molarity buffer. Protein Expres Purif 2003;32:83–8.
- [12] Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The protein data bank. Nucleic Acids Res 2000;28:235–42.
- [13] Schuttelkopf AW, van Aalten DM. Prodrg: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 2004;60:1355–63.
- [14] DeLano WL. The pymol molecular graphics system. San Carlos, CA, USA: DeLano Scientific; 2002.
- [15] Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;24:236–44.
- [16] Amundson SA, Do KT, Vinikoor LC, Lee RA, Koch-Paiz CA, Ahn J, et al. Integrating global gene expression and radiation survival parameters across the 60 cell lines of the national cancer institute anticancer drug screen. Cancer Res 2008;68:415–24.
- [17] Wosikowski K, Schuurhuis D, Johnson K, Paull KD, Myers TG, Weinstein JN, et al. Identification of epidermal growth factor receptor and c-erbb2 pathway inhibitors by correlation with gene expression patterns. J Natl Cancer Inst 1997:89:1505-15.
- [18] Efferth T, Fabry U, Osieka R. Apoptosis and resistance to daunorubicin in human leukemic cells. Leukemia 1997;11:1180-6.
- [19] Gigant B, Wang C, Ravelli RB, Roussi F, Steinmetz MO, Curmi PA, et al. Structural basis for the regulation of tubulin by vinblastine. Nature 2005;435:519–22.
- [20] Sobolev V, Sorokine A, Prilusky J, Abola EE, Edelman M. Automated analysis of interatomic contacts in proteins. Bioinformatics 1999:15:327–32.
- [21] Tang Z, Yang L, Zu Y, Guo X. Variations of vinblastine accumulation and redox state affected by exogenous h2o2 in catharanthus roseus (l.) g. Don. Plant Growth Regul 2009;57:15–20.
- [22] Quintyne NJ, Reing JE, Hoffelder DR, Gollin SM, Saunders WS. Spindle multipolarity is prevented by centrosomal clustering. Science 2005;307:127–9.
- [23] Prakash V, Timasheff SN. Mechanism of interaction of vinca alkaloids with tubulin: catharanthine and vindoline. Biochemistry 1991;30:873–80.
- [24] Cohen-Kashi Malina K, Cooper I, Teichberg VI. Closing the gap between the invivo and in-vitro blood-brain barrier tightness. Brain Res 2009;1284: 12–21.